Evidence map›Paper›PMID 40417265›Full record

ArticleCrystal growth & design2025

Discovery of Cilnidipine Cocrystals with Enhanced Dissolution by the Use of Computational Tools and Semiautomatic High-Throughput Screening.

Matteo Guidetti, Rolf Hilfiker, Susan M De Paul, Annette Bauer-Brandl, Fritz Blatter, Martin Kuentz

Abstract read
In one paragraph

Article in Crystal growth & design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matteo GuidettiSolid-State Development Department, Solvias AG, Römerpark 2, CH- 4303 Kaiseraugst, Switzerland.ORCID https://orcid.org/0009-0009-9430-7030
Rolf HilfikerSolid-State Development Department, Solvias AG, Römerpark 2, CH- 4303 Kaiseraugst, Switzerland.
Susan M De PaulSolid-State Development Department, Solvias AG, Römerpark 2, CH- 4303 Kaiseraugst, Switzerland.
Annette Bauer-BrandlDepartment of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark.
Fritz BlatterSolid-State Development Department, Solvias AG, Römerpark 2, CH- 4303 Kaiseraugst, Switzerland.ORCID https://orcid.org/0000-0002-2879-9577
Martin KuentzInstitute of Pharma Technology, University of Applied Sciences and Arts Northwestern Switzerland, CH- 4132 Muttenz, Switzerland.ORCID https://orcid.org/0000-0003-2963-2645

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cocrystals are an attractive option for overcoming drug limitations, such as a low dissolution rate and absorption of poorly water-soluble compounds. Nevertheless, the discovery of new cocrystals remains a trial-and-error approach in which hundreds of coformers and several experimental methods are often tested. To streamline the cocrystal screening, computational methods can be used to select the coformers most likely to form a cocrystal, while high-throughput screening (HTS) approaches can rapidly screen them experimentally. In this manuscript, a new cocrystal of the extremely poorly soluble drug cilnidipine (solubility ≈30 ng/mL, 0.06 μM) was successfully discovered by applying HTS approaches. Only one cocrystal resulted from the screening with a total of 52 coformers, whereby the computational approach molecular complementarity successfully ranked this coformer (

Identifiers

PMID40417265
PMCPMC12100653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.